<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence</h1>
    <p class="timestamp">Published: 2024-12-27 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, Agency, or we) is announcing that we have concluded that certain statements set forth in the FDA-approved labeling for buprenorphine-containing transmucosal products for the treatment of opioid dependence (BTODs) related to the recommended maintenance dosage and dosage adjustments during pregnancy can be modified. We believe that certain statements in BTOD labeling can be modified because the labeling for these products may be misinterpreted by some as esta...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-30776</p>
    <p><strong>Publication Date:</strong> 2024-12-27</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/12/27/2024-30776/modifications-to-labeling-of-buprenorphine-containing-transmucosal-products-for-the-treatment-of">https://www.federalregister.gov/documents/2024/12/27/2024-30776/modifications-to-labeling-of-buprenorphine-containing-transmucosal-products-for-the-treatment-of</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-30776</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
